Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | PPIG | Q13427 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 5/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444355 | 0.87 | SMO (0.42) | HSP90AA1HSP90AB1SMOROCK2 | |
| SCHEMBL31444295 | 0.84 | PDE5A (0.46) | HSP90AA1HSP90AB1PDE5AROCK2FFAR2 | |
| SCHEMBL31444378 | 0.80 | RIPK1 (0.41) | HSP90AA1HSP90AB1FFAR2NTRK1RIPK1 | |
| SCHEMBL31444410 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1FFAR2NTRK1 | |
| SCHEMBL31444405 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1FFAR2NTRK1 | |
| SCHEMBL31444272 | 0.79 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1PPIDPPIGPDE5A | |
| SCHEMBL31444231 | 0.76 | SCN9A (0.41) | HSP90AA1HSP90AB1FFAR2NTRK1 | |
| SCHEMBL31444445 | 0.76 | RAB9A (0.50) | HSP90AA1HSP90AB1ROCK2FFAR2 | |
| SCHEMBL21732087 | 0.75 | NTRK1 (0.54) | NTRK1RIPK1 | |
| SCHEMBL21723201 | 0.75 | NTRK1 (0.54) | NTRK1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |